






Supplementary Figure 1 Kaplan-Meier curves for overall survival and progression-free survival of patients treated with locoregional- bevacizumab-immunotherapy. A-E and G-K: OS(A-E) and PFS(G-K) in patients stratified into groups according to CRP(A,G),

ALB(B,H), PIVKA-II(C,I), TBIL(D,J) and MVI(E,K); F and L: Comparisons of OS(F) and PFS(L) in patients receiving atezo+bev or sint+bev as systemic therapies. CRP, C-reactive protein; ALB, albumin; PIVKA-II, protein induced by vitamin K absence or antagonist-II; TBIL, total bilirubin; MVI, macrovascular invasion; atezo, atezolizumab; bev, bevacizumab; sint, sintilimab.




Supplementary Figure 2 Landmark analysis of overall survival according to CRAPT-M, CRAFTY, and simple-CRAPT-M models in patients treated with locoregional-bevacizumab-immunotherapy. A: Kaplan-Meier OS curves at the 6-month landmark, stratified by CRAPT-M; B: Kaplan-Meier OS curves at the 6-month landmark, stratified by CRAFTY; C: Kaplan-Meier OS curves at the 12-month landmark, stratified by CRAPT-M; D: Kaplan-Meier OS curves at the 12-month landmark, stratified by CRAFTY; E: Kaplan-Meier OS curves at the 6-month landmark, stratified by Simple-CRAPT-M; F: Kaplan-Meier OS curves at the 12-month landmark, stratified by Simple-CRAPT-M.




Supplementary Figure 3 Landmark analysis of progression-free survival according to CRAPT-M, CRAFTY, and simple-CRAPT-M models in patients treated with locoregional-bevacizumab-immunotherapy. A: Kaplan-Meier PFS curves at the 6-month landmark, stratified by CRAPT-M; B: Kaplan-Meier PFS curves at the 6-month landmark, stratified by CRAFTY; C: Kaplan-Meier PFS curves at the 12-month landmark, stratified by CRAPT-M; D: Kaplan-Meier PFS curves at the 12-month landmark, stratified by CRAFTY;

E: Kaplan-Meier PFS curves at the 6-month landmark, stratified by Simple-CRAPT-M; F: Kaplan-Meier PFS curves at the 12-month landmark, stratified by Simple-CRAPT-M.




Supplementary Figure 4 Subgroup analysis for patients receiving atezo+bev or sint+bev as systemic therapies. A and B: OS(A) and PFS(B) in patients stratified into different groups according to the CRAPT-M model; C and D: OS(C) and PFS(D) in patients stratified into different groups according to the CRAFTY model. atezo, atezolizumab; bev, bevacizumab; sint, sintilimab.




Supplementary Figure 5 Calibration plots of the CRAPT-M for predicting overall survival and progression-free survival in patients treated with locoregional-bevacizumab-immunotherapy. A: Calibration of the CRAPT-M for predicting 12-month OS; B: Calibration of the CRAPT-M for predicting 24-month OS; C: Calibration of the CRAPT-M for predicting 6-month PFS; D: Calibration of the CRAPT-M for predicting 12-month PFS.


A




B



C




D




Supplementary Figure 6 Calibration plots of the CRAFIT for predicting overall survival and progression-free survival in patients treated with locoregional-bevacizumab-immunotherapy. A: Calibration of the CRAFIT for predicting 12-month OS; B: Calibration of the CRAFIT for predicting 24-month OS; C: Calibration of the CRAFIT for predicting 6-month PFS; D: Calibration of the CRAFIT for predicting 12-month PFS.


A




B



C




D




Supplementary Figure 7 Decision curve analysis of the CRAPT-M, CRAFTY, and simple-CRAPT-M for predicting overall survival and progression-free survival in patients treated with locoregional-bevacizumab-immunotherapy. A: DCA for predicting 12-month OS, comparing the net benefit of CRAPT-M, CRAFTY, simple-CRAPT-M; B: DCA for predicting 24-month OS, comparing the net benefit of CRAPT-M, CRAFTY, simple-CRAPT-M; C: DCA for predicting 6-month PFS, comparing the net benefit of CRAPT-M, CRAFTY, simple-CRAPT-M; D: DCA for predicting 12-month PFS, comparing the net benefit of CRAPT-M, CRAFTY, simple-CRAPT-M.


A




B



C



D



Supplementary Figure 8 Calibration plots of the Simple-CRAPT-M for predicting overall survival and progression-free survival in patients treated with locoregional-bevacizumab-immunotherapy. A: Calibration of the Simple-CRAPT-M for predicting 12-month OS; B: Calibration of the Simple-CRAPT-M for predicting 24-month OS; C: Calibration of the Simple-CRAPT-M for predicting 6-month PFS; D: Calibration of the Simple-CRAPT-M for predicting 12-month PFS.